Antitope Ltd. Announces Antibody Research Agreement With Boehringer Ingelheim

Cambridge UK, 27 October 2008 - Antitope Ltd. ("Antitope") today announced a research agreement with Boehringer Ingelheim ("Boehringer Ingelheim") for the modification of monoclonal antibodies.

Under the Agreement, Antitope will apply its proprietary Composite Human AntibodyTM technology for the humanization of Boehringer Ingelheim's therapeutic antibodies.

"We are delighted to be working with Boehringer Ingelheim to produce humanized antibodies with low immunogenic potential," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. "This partnership utilises Antitope's expertise in creating humanised antibodies devoid of T cell epitopes to complement Boehringer Ingelheim's innovation in developing novel therapeutics based on monoclonal antibodies."

About Antitope

Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary Composite Human AntibodyTM technology builds upon the previous pioneering work of its founders in the detection and removal of T cell epitopes in antibodies/proteins. Antitope is a privately-held company and has established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope, please visit http://www.antitope.co.uk/.

For further information contact:

Dr Neil Butt

Business Development Director, Antitope Ltd.

Tel: +44 (0)1223 496190

Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it